HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea · Delayed Price · Currency is KRW 3,320.00
+195.00 (6.24%)
Apr 10, 2026, 3:30 PM KST
HLB Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 69,561 | 54,932 | 52,591 | 42,403 | 43,586 |
Other Revenue | -0 | - | -0 | -0 | - |
| 69,561 | 54,932 | 52,591 | 42,403 | 43,586 | |
Revenue Growth (YoY) | 26.63% | 4.45% | 24.03% | -2.72% | 1.53% |
Cost of Revenue | 59,529 | 44,953 | 45,406 | 33,682 | 38,579 |
Gross Profit | 10,032 | 9,979 | 7,184 | 8,721 | 5,007 |
Selling, General & Admin | 11,966 | 16,192 | 15,236 | 15,673 | 15,641 |
Amortization of Goodwill & Intangibles | 33.62 | 114.26 | 48.3 | 20.79 | 99.66 |
Other Operating Expenses | 249.32 | 301.46 | 183 | 273.11 | 240.04 |
Operating Expenses | 13,614 | 17,603 | 16,053 | 16,228 | 16,094 |
Operating Income | -3,582 | -7,624 | -8,869 | -7,507 | -11,087 |
Interest Expense | -1,916 | -1,964 | -1,112 | -5,146 | -1,160 |
Interest & Investment Income | 639.72 | 984.55 | 1,166 | 1,230 | 96.09 |
Earnings From Equity Investments | -7,594 | -433.03 | 802.4 | - | - |
Currency Exchange Gain (Loss) | 189.49 | 4,482 | 94.65 | 327.03 | 97.78 |
Other Non Operating Income (Expenses) | -163.03 | 1,363 | -3,430 | -1,334 | 15.88 |
EBT Excluding Unusual Items | -12,427 | -3,193 | -11,347 | -12,430 | -12,038 |
Gain (Loss) on Sale of Investments | 3,016 | -11,678 | 7,754 | 1,879 | -359.48 |
Gain (Loss) on Sale of Assets | 234.25 | -17.69 | 4.04 | -598.18 | -14.8 |
Asset Writedown | -22.72 | -8,037 | - | -424.08 | -4,632 |
Other Unusual Items | -1,887 | - | 624.11 | - | -720.83 |
Pretax Income | -11,086 | -22,926 | -2,965 | -11,573 | -17,764 |
Income Tax Expense | -1,418 | - | - | - | - |
Earnings From Continuing Operations | -9,668 | -22,926 | -2,965 | -11,573 | -17,764 |
Earnings From Discontinued Operations | - | -534.08 | -113.98 | -530.86 | - |
Net Income to Company | -9,668 | -23,460 | -3,079 | -12,104 | -17,764 |
Minority Interest in Earnings | 441.2 | 666.96 | 777.16 | 750.45 | 567.08 |
Net Income | -9,227 | -22,793 | -2,302 | -11,354 | -17,197 |
Net Income to Common | -9,227 | -22,793 | -2,302 | -11,354 | -17,197 |
Shares Outstanding (Basic) | 88 | 84 | 82 | 71 | 64 |
Shares Outstanding (Diluted) | 88 | 84 | 82 | 71 | 64 |
Shares Change (YoY) | 4.09% | 3.23% | 14.46% | 10.86% | 7.26% |
EPS (Basic) | -105.00 | -270.00 | -28.15 | -158.92 | -266.85 |
EPS (Diluted) | -105.00 | -270.00 | -28.15 | -158.92 | -266.85 |
Free Cash Flow | -9,463 | 650.79 | 3,025 | -12,204 | -12,091 |
Free Cash Flow Per Share | -107.69 | 7.71 | 36.99 | -170.82 | -187.61 |
Gross Margin | 14.42% | 18.17% | 13.66% | 20.57% | 11.49% |
Operating Margin | -5.15% | -13.88% | -16.86% | -17.70% | -25.44% |
Profit Margin | -13.26% | -41.49% | -4.38% | -26.78% | -39.45% |
Free Cash Flow Margin | -13.60% | 1.19% | 5.75% | -28.78% | -27.74% |
EBITDA | 1,040 | 467.85 | -389.34 | -5,841 | -9,386 |
EBITDA Margin | 1.50% | 0.85% | -0.74% | -13.78% | -21.54% |
D&A For EBITDA | 4,622 | 8,092 | 8,479 | 1,666 | 1,701 |
EBIT | -3,582 | -7,624 | -8,869 | -7,507 | -11,087 |
EBIT Margin | -5.15% | -13.88% | -16.86% | -17.70% | -25.44% |
Advertising Expenses | - | 0.69 | - | 0.21 | 7.07 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.